JPH0232006A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPH0232006A JPH0232006A JP18022888A JP18022888A JPH0232006A JP H0232006 A JPH0232006 A JP H0232006A JP 18022888 A JP18022888 A JP 18022888A JP 18022888 A JP18022888 A JP 18022888A JP H0232006 A JPH0232006 A JP H0232006A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- external preparation
- nicorandil
- active ingredient
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002497 nicorandil Drugs 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 7
- 208000017520 skin disease Diseases 0.000 abstract description 5
- -1 N-(2hydroxyethyl)nicotinic acid amide nitrate ester Chemical class 0.000 abstract description 4
- 206010042496 Sunburn Diseases 0.000 abstract description 4
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 3
- 239000006071 cream Substances 0.000 abstract description 2
- 239000006185 dispersion Substances 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 208000010201 Exanthema Diseases 0.000 abstract 1
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 201000005884 exanthem Diseases 0.000 abstract 1
- 206010037844 rash Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000033830 Hot Flashes Diseases 0.000 description 6
- 206010060800 Hot flush Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚外用剤、特に皮膚障害、及び皮膚の生理的
老化を防止・改善する皮膚外用剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to an external skin preparation, particularly to an external skin preparation that prevents and improves skin disorders and physiological aging of the skin.
[従来の技14テ]
[発明が解決しようとする課題]
′ 、 s占
しかしながら、従来の皮膚外用剤では、日焼は後のほて
り、カミソリまけ、肌荒れなど及び皮膚の生理的老化を
防止及び改善する効果は不十分であり、これらの効果の
優れた皮膚外用剤が待望されているが、いまだ十分なも
のは提供されていない。[Conventional Techniques 14] [Problems to be Solved by the Invention] However, conventional skin preparations do not prevent sunburn from causing hot flashes, razor burn, rough skin, etc. and physiological aging of the skin. The improvement effect is insufficient, and although there is a long-awaited topical skin preparation with excellent these effects, no sufficient product has been provided yet.
溌」肥のj■劇
本発明は前記従来技術の問題点に鑑みなされたものであ
り、その目的は皮膚の障害及び生理的老化を効果的に防
止することのできる皮膚外用剤を提供することにある。The present invention was made in view of the problems of the prior art, and its purpose is to provide an external preparation for skin that can effectively prevent skin disorders and physiological aging. be.
前記目的を達成するために、本発明者らは皮膚に対し特
1軟的な有効性を有する原料を得るべく鋭意研究を重ね
た結果、肌荒れ、カミソリまけ、肌のほてり等の皮膚障
害及び皮膚の生理的老化を防止及び改善する効果に侵れ
る物質としてニコランジルおよびその塩類に着目し、本
発明を解決するに至った。In order to achieve the above object, the present inventors have conducted intensive research to obtain raw materials that have a particularly soothing effect on the skin. The present invention has been achieved by focusing on nicorandil and its salts as substances that have the effect of preventing and improving physiological aging.
[護国を解決するための手段]
すなわち、請求項記載の発明は、ニコランジルまたはそ
の塩類を含むことを特徴とする皮膚外用剤である。[Means for Solving the Problem of Protecting the Country] That is, the claimed invention is an external skin preparation characterized by containing nicorandil or its salts.
以下本発明について詳しく説明する。The present invention will be explained in detail below.
本発明におけるニコランジルは本邦で発明開発された(
永野洋幸ほか2日本薬学会第98回抄録集、232.1
978)狭心症治療薬である。冠血管拡張作用、冠動脈
彎縮抑制作用を有するものの、心血行動態および心機能
に及ぼす影響が少なく各種病型の狭心症治療薬として有
効な薬物である(特公昭58−17463号、特開昭5
3−9323号)。その薬理作用は循環器系に関しては
多数の報告がなされているが、その他の部位については
臨床用量の100倍以上量を投与した場合に中枢神経系
および腎機能に軽度な変化を示したという報告がなされ
ているだけである。Nicorandil in the present invention was invented and developed in Japan (
Hiroyuki Nagano et al. 2 Proceedings of the 98th meeting of the Pharmaceutical Society of Japan, 232.1
978) It is a drug for treating angina pectoris. Although it has a coronary vasodilator effect and an inhibitory effect on coronary artery curvature, it has little effect on cardiac hemodynamics and cardiac function, making it an effective drug for the treatment of various types of angina (Japanese Patent Publication No. 17463/1989, Showa 5
3-9323). Many reports have been made regarding its pharmacological effects on the circulatory system, but there have been reports of mild changes in the central nervous system and renal function when administered in doses 100 times or more of the clinical dose in other areas. is being done.
しかし、皮膚外用剤領域への応用はまったく知られてい
なかった。However, its application to the field of external skin preparations was completely unknown.
本発明において、ニコランジルまたはその塩類の皮膚外
用剤への配合量は、通常皮膚外用剤全量中0.0000
1〜10 (重量%)、好まシクハ0.0o01〜5(
重量%)、さらに好ましくは0.01〜1(重量%)で
ある。0.00001%以下では本発明の効果が十分に
得られず、また10%以上では製剤上不利である本発明
の皮膚外用剤は、前記ニコランジルまたはその塩類の必
須成分に加えて、必要に応じ本発明の効果を損なわない
範囲内で皮膚外用剤に一般に用いられる各種成分、すな
わち水性成分、粉末成分、油分、界面活性剤、保湿剤、
増粘剤、防腐剤、酸化防止剤、香料、色素などを配合す
ることができる。In the present invention, the amount of nicorandil or its salts added to the skin external preparation is usually 0.0000 in the total amount of the skin external preparation.
1-10 (wt%), preferably Shikuha 0.0o01-5 (
(% by weight), more preferably from 0.01 to 1 (% by weight). If it is less than 0.00001%, the effect of the present invention cannot be sufficiently obtained, and if it is more than 10%, it is disadvantageous in terms of formulation. Various ingredients commonly used in external skin preparations within a range that does not impair the effects of the present invention, namely aqueous ingredients, powder ingredients, oils, surfactants, humectants,
Thickeners, preservatives, antioxidants, fragrances, pigments, etc. can be added.
また、本発明の皮膚外用剤の剤型は任意であり、例えば
化粧水などの可溶化系、乳液、クリームなどの乳化系あ
るいはファンデーション、分散液などの剤型をとること
ができる。Moreover, the dosage form of the skin external preparation of the present invention is arbitrary, and can be, for example, a solubilized system such as a lotion, an emulsified system such as a milky lotion or a cream, or a dosage form such as a foundation or a dispersion.
[実施例1 次に実施例により本発明をざらに詳細に説明する。[Example 1 Next, the present invention will be explained in more detail with reference to Examples.
なお、本発明はこれによって限定されるものではない。Note that the present invention is not limited to this.
ニ − ゝ S゛
ニコランジルを用いた本発明にかかる皮膚外用剤の外皮
適用による効果を、下記の方法による実使用テストを実
施し、肌のほてり、肌荒れ、カミソリまけに対する改善
率から評価した。The effects of applying the external skin preparation of the present invention using Ni-S'nicorandil to the skin were evaluated in terms of improvement rates for skin hot flashes, rough skin, and razor bumps by carrying out a practical test using the method described below.
日焼は後の肌のほてりあるいは肌荒れの症状で悩む被験
者各2o名で実施し、第1表に示す組成のローションを
顔面に塗布し、日焼は後のほてり及び1週間後の肌の状
態を判定した。Sunburn was conducted on 2 subjects each who suffered from symptoms of hot flashes or rough skin after sunburn, and a lotion with the composition shown in Table 1 was applied to the face. was determined.
また、カミソリまけする男性被験者20名を対象に、髭
剃り直後に同じく第1表に示すローションを塗布し、カ
ミソリまけに対する効果を判定した。In addition, the lotions shown in Table 1 were applied to 20 male test subjects who shaved their beards immediately after shaving, and the effects on shaving were evaluated.
判定結果を第2表に示す。The determination results are shown in Table 2.
なお、各判定基準は、以下の通りとした。The criteria for each evaluation were as follows.
日焼は後の肌のほてりまたは肌荒れに対する改善効果
著効:症状の消失したもの
有効:症状が弱くなったもの
やや有効:症状がやや弱くなったもの
無効:症状に変化を認めないもの
カミソリまけに対する改善効果
著効:カミソリまけの消失したちの
有効:カミソリまけが非常に改善したちのやや有効:カ
ミソリまけかやや改善したもの無効:カミソリまけに変
化を認めないもの判定
0:被験者が著効、有効及びやや有効を示す割合(有効
率)が80%以上
O:被験者が著効、有効及びやや有効を示す割合(有効
率)が50〜80%
×:被験者が著効、有効及びやや有効を示す割合(有効
率)が50%以下
実施例上−2
第
表
(配合量は重量%)
(以下余白)
(以下余白)
次の第2表に:H定結果を示す。Improving effect on hot flashes or rough skin after sun exposure: Significantly effective: Symptoms disappeared Effective: Symptoms weakened Slightly effective: Symptoms slightly weakened Ineffective: No change observed in symptoms Significant improvement effect: Effective after the razor sharpness disappears: Effective after the razor sharpness disappears: Slightly effective after the razor sharpness has improved significantly: Razor sharpness has slightly improved Ineffective: No change is observed in the razor sharpness Judgment 0: Subject notices The percentage of subjects showing excellent, effective, and somewhat effective (effectiveness rate) is 80% or more O: The percentage of subjects showing excellent, effective, and somewhat effective (effectiveness rate) is 50 to 80% ×: The percentage of subjects showing excellent, effective, and somewhat effective The ratio showing effectiveness (effectiveness rate) is 50% or less Example 1-2 Table 2 (Amounts are weight %) (Hereinafter in the margin) (Hereinafter in the margin) The following Table 2 shows the H constant results.
第2表
第2表からも明らかなように、ニコランジルは、0.0
1ないし0.0001%で日焼は後の肌のほてり、肌荒
れ及びカミソリまけに対して優れた改善効果を示した。Table 2 As is clear from Table 2, nicorandil is 0.0
At a concentration of 1 to 0.0001%, tanning showed an excellent improvement effect on hot flashes, rough skin, and razor burn after tanning.
以下にその他の実施例を示すが、いずれも同様の実使用
テストの結果、日焼は後のほてり、肌荒れあるいはカミ
ソリまけに対して優れた改善効果をボした。Other examples are shown below, but as a result of the same actual test, it was found that sun tanning had an excellent improvement effect on later hot flashes, rough skin, and razor burn.
なお、配合量は重量%で示している。In addition, the blending amount is shown in weight%.
実施例3 化粧水
(1)ニコランジル 0.0001(2
)グリセリン 4.0(3)1.3−
ブチレングリコール 4.0(4)エタノール
7.0(5)ポリオキシエレン(20
モル)
オレイルアルコール 0.5
(6)メチルパラベン 0.05(7ンク
エン# 0.01(8)クエン
酸ナトリウム 0.1(9)香料
0.01(10)精製水
残余製法は以下の通りである。Example 3 Lotion (1) Nicorandil 0.0001 (2
) Glycerin 4.0 (3) 1.3-
Butylene glycol 4.0(4) Ethanol
7.0 (5) Polyoxyethylene (20
Mol) Oleyl Alcohol 0.5 (6) Methylparaben 0.05 (7) Citric #0.01 (8) Sodium Citrate 0.1 (9) Fragrance
0.01 (10) Purified water
The remaining manufacturing method is as follows.
まず、精製水にグリセリン、1,3−ブチレングリコー
ル、クエン酸、クエン酸ナトリウムを溶解する。First, glycerin, 1,3-butylene glycol, citric acid, and sodium citrate are dissolved in purified water.
また、別にエタノールにニコランジル、ポリオキシエチ
レン(20モル)オレイルアルコール、メチルパラベン
、香料を溶解し、これを前記精製水溶液に加えて溶解し
、濾過して化粧水を得た。Separately, nicorandil, polyoxyethylene (20 mol), oleyl alcohol, methyl paraben, and fragrance were dissolved in ethanol, added to the purified aqueous solution, dissolved, and filtered to obtain a lotion.
実施例4 パック
(1)ニコランジル o、oos(2
)ポリビニルアルコール 15.0(3)ポリエ
チレングリコール 3.0(4)プロピレングリ
コール 7.0(5)エタノール
10.0(6)メチルパラベン
0.05(7)香料 0.
05(8)精製水 残余製法は
以下の通りである。Example 4 Pack (1) Nicorandil o, oos (2
) Polyvinyl alcohol 15.0 (3) Polyethylene glycol 3.0 (4) Propylene glycol 7.0 (5) Ethanol
10.0(6) Methylparaben
0.05 (7) Fragrance 0.
05(8) Purified water The remaining manufacturing method is as follows.
まず、精製水にポリエチレングリコール、プロピレング
リコール、メチルパラベンを加え撹拌溶解する。First, polyethylene glycol, propylene glycol, and methylparaben are added to purified water and dissolved with stirring.
次にポリビニルアルコールを加え加熱撹拌し、香料を溶
解したエタノール及びニコランジルを加え撹拌溶解して
バックを得た。Next, polyvinyl alcohol was added and stirred with heating, and ethanol and nicorandil in which the fragrance had been dissolved were added and dissolved with stirring to obtain a bag.
実施例5 固形白粉
(1)タルク 85.4(2)
ステアリン酸 1.5(3)ラノリン
5.0(4)スクワラン
5.0(5)ソルビタンセスキ
オレイン酸エステル 2.0
(6)トリエタノールアミン 1.0(7)ニ
コランジル 0.05(8)顔料
適量(9)香料
適量製法は以下の通りである。Example 5 Solid white powder (1) Talc 85.4 (2)
Stearic acid 1.5 (3) Lanolin 5.0 (4) Squalane
5.0 (5) Sorbitan sesquioleate 2.0 (6) Triethanolamine 1.0 (7) Nicorandil 0.05 (8) Pigment
Appropriate amount (9) Fragrance
The appropriate amount manufacturing method is as follows.
まず、タルク、顔料をニーダ−で十分混合する(粉末部
)。First, talc and pigment are thoroughly mixed in a kneader (powder part).
そして、トリエタノールアミンを50%相当量の精製水
に加え70℃に保つ(水相)
香料をのぞく他の成分を混合し、加熱溶解する(油相)
。Then, add triethanolamine to 50% equivalent amount of purified water and keep it at 70℃ (water phase). Mix other ingredients except fragrance and dissolve by heating (oil phase).
.
水相に油相を加えホモミキサーで均一に乳化し、これを
粉末部に加えニーダ−で練り合わせた後、水分を蒸発さ
せ、粉砕機で処理する。The oil phase is added to the water phase and uniformly emulsified using a homomixer, and this is added to the powder portion and kneaded using a kneader.The water is then evaporated and the mixture is processed using a pulverizer.
ざらにこれをよくかキ混ぜながら香料を均一に噴霧し、
圧縮成形して固形白粉を得た。Stir this well in a colander and spray the fragrance evenly.
A solid white powder was obtained by compression molding.
[発明の効果]
本発明は以上説明したように構成されているので、以下
に記載されるような効果を奏する。[Effects of the Invention] Since the present invention is configured as described above, it produces the effects described below.
請求項記載の発明によれば、皮膚外用剤にニコランジル
またはその塩類をを配合したので、皮膚障害、皮膚の生
理的老化を効果的に防止及び改善することができる。According to the claimed invention, since nicorandil or its salts are blended into the skin external preparation, skin disorders and physiological aging of the skin can be effectively prevented and improved.
特許出願人 株式会社 資生堂Patent applicant: Shiseido Co., Ltd.
Claims (1)
ミド硝酸エステル(一般名:ニコランジル)または、そ
の塩類を有効成分とする皮膚外用剤。[Claims] N-(2-hydroxyethyl)nicotinamide nitrate (generic name: nicorandil) represented by the following structural formula ▲ Numerical formula, chemical formula, table, etc. ▼ or its salts as an active ingredient External skin preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18022888A JPH0232006A (en) | 1988-07-21 | 1988-07-21 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP18022888A JPH0232006A (en) | 1988-07-21 | 1988-07-21 | External preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0232006A true JPH0232006A (en) | 1990-02-01 |
Family
ID=16079619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP18022888A Pending JPH0232006A (en) | 1988-07-21 | 1988-07-21 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0232006A (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039733A1 (en) * | 1996-04-23 | 1997-10-30 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
WO1998015260A1 (en) * | 1996-10-08 | 1998-04-16 | Kao Corporation | Wrinkling modifiers |
US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
WO1999047141A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Method of treating skin irritation |
JP2002275158A (en) * | 2001-03-21 | 2002-09-25 | Torrent Pharmaceuticals Ltd | New compound usable for controlling diabetic vascular complication associated with aging, method for producing the same and therapeutic use thereof |
WO2006097348A1 (en) * | 2005-03-15 | 2006-09-21 | L'oreal | Use of agents such as nonpolymeric nitric oxide donors for making the lips full again and/or colouring the lips |
FR2883177A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Use of cosmetic agent e.g. as a makeup agent, care composition for the lips, an agent for stimulating the naturally pinkish coloration of the lips, lipstick, liquid gloss, lip paste, lipliner pencil, lip balm and lip varnish |
FR2883170A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Cosmetic use of an agent supporting production of nitric oxide in and/or on the skin or agents supporting cutaneous microcirculation for care and/or make-up of the skin |
FR2883171A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Cosmetic use of an agent supporting the production of nitric oxide in and/or on the skin or agents supporting cutaneous microcirculation for care and/or make-up of eye contour e.g. to decrease pockets and/or periocular rings |
-
1988
- 1988-07-21 JP JP18022888A patent/JPH0232006A/en active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
WO1997039733A1 (en) * | 1996-04-23 | 1997-10-30 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
JPH11508281A (en) * | 1996-04-23 | 1999-07-21 | ザ、プロクター、エンド、ギャンブル、カンパニー | How to adjust the appearance of skin with Vitamin B compounds |
WO1998015260A1 (en) * | 1996-10-08 | 1998-04-16 | Kao Corporation | Wrinkling modifiers |
US6436920B1 (en) | 1996-10-08 | 2002-08-20 | Kao Corporation | Wrinkling modifiers |
WO1999047141A1 (en) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Method of treating skin irritation |
JP2002275158A (en) * | 2001-03-21 | 2002-09-25 | Torrent Pharmaceuticals Ltd | New compound usable for controlling diabetic vascular complication associated with aging, method for producing the same and therapeutic use thereof |
WO2006097348A1 (en) * | 2005-03-15 | 2006-09-21 | L'oreal | Use of agents such as nonpolymeric nitric oxide donors for making the lips full again and/or colouring the lips |
FR2883177A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Use of cosmetic agent e.g. as a makeup agent, care composition for the lips, an agent for stimulating the naturally pinkish coloration of the lips, lipstick, liquid gloss, lip paste, lipliner pencil, lip balm and lip varnish |
FR2883170A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Cosmetic use of an agent supporting production of nitric oxide in and/or on the skin or agents supporting cutaneous microcirculation for care and/or make-up of the skin |
FR2883171A1 (en) * | 2005-03-15 | 2006-09-22 | Oreal | Cosmetic use of an agent supporting the production of nitric oxide in and/or on the skin or agents supporting cutaneous microcirculation for care and/or make-up of eye contour e.g. to decrease pockets and/or periocular rings |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4252899B2 (en) | Topically applied composition containing multivesicular emulsion and method for producing the same | |
JPH0193519A (en) | Antipigmentation drug for external use | |
JP2937446B2 (en) | Blackening agent to prevent gray hair | |
JP2764510B2 (en) | Whitening cosmetics | |
JPH0232006A (en) | External preparation for skin | |
JPS6245527A (en) | Preventive and remedy for gray hair | |
JPH0745387B2 (en) | Hair growth and hair growth promoter | |
JPS61260010A (en) | Hair growing agent | |
JPS6130509A (en) | Dermal external drug | |
JPH09241137A (en) | Hair crowing and restoring agent | |
JP2786674B2 (en) | External preparation for improving rough skin | |
JP2906269B2 (en) | External preparation for skin | |
JP2002265358A (en) | Skin care preparation for dealing with stress | |
JPH04305519A (en) | Skin humectant for external use | |
JPH02311411A (en) | Hair-culturing agent | |
JPH0354081B2 (en) | ||
JPH11255621A (en) | Cosmetic for scalp and hair | |
JPH02221213A (en) | Skin cosmetic | |
JP2000256168A (en) | Skin lotion | |
JP3962166B2 (en) | Topical skin preparation | |
JP3193617B2 (en) | Refreshing agent and composition for human body | |
JPS60116616A (en) | Cosmetic | |
JPH1017440A (en) | Hair growing and restoring agent | |
JPS63267711A (en) | Cosmetic | |
JPH07149787A (en) | Astringent and binding compound and preparation for medical and cosmetic use |